Abstract: Objective：To analysis the curative effect and adverse reactions of non-small cell lung cancer with malignant pleural effusion patients received different doses，Endostar combined with cisplatin intracavity perfusion.Methods：60 patients with non-small cell lung cancer with malignant pleural effusion， in January 2014- August 2015， were divided into 2 groups using a simple method of randomization， both to give grace and cisplatin plus intracavity perfusion therapy， the control group given cisplatin 40 mg·m-2 dl and Endostar 45 mg d2 and experimental group cisplatin for a 40 mg·m-2 dl and Endostar 45 mg d2， d5.Results： Experimental group disease remission rate (76.67%)， disease control rates (90.00%) is significantly higher than control group in disease remission rate (50.00%)， disease control rates (66.67%)， P<0.05； Difference of adverse reactions between two groups is small， P>0.05.Conclusion：Curative effect of high dose Endostar combined with cisplatin is better for Non-small cell lung cancer with malignant patients, and the adverse reactions don’t increase. It should be based on the specific patient and tolerance to choose reasonable dose for patients with treatment to promote the improvement of the prognosis.